Adipotide: A Metabolic Research Overview
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
- Adipotide (also called FTPP) is an experimental peptide-like compound. Researchers designed it to find the blood vessels that feed white body fat and shut those vessels down so the fat shrinks.
- The most-cited research is a 2011 study in obese monkeys, where researchers reported weight loss and better blood-sugar handling. The same preclinical work also reported kidney-toxicity warning signs.
- Be clear about the evidence: it is all animal and lab work. There are no completed human trials showing it works, and its safety in people has not been established, so any human claims you see are unverified.
- It is not approved by the FDA or any similar authority for any use. It remains an investigational research compound.
- BioRegen sells Adipotide strictly for laboratory and educational research only, not for human or veterinary use, and makes no claim that it works.
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. Adipotide, also written as FTPP (short for fat-targeted proapoptotic peptide), is a lab-made molecule built to act like a small protein. It has drawn attention in published studies because of how researchers think it works: by going after the blood vessels that feed white fat tissue. This overview pulls together how scientists describe Adipotide in early, animal-stage research. It looks at how the molecule is designed, how it is thought to work, and the questions that still have no answer. It is written for researchers and students who want a quick map of this corner of metabolic research. It is not a guide for using the compound in any way.
What Adipotide (FTPP) Is in the Research Literature
Published research describes Adipotide as a molecule made of two parts stuck together, each with its own job. The first part is a "homing" piece (a short sequence written as CKGGRAKDC). Scientists found it using a lab screening method in animals, and it tends to stick to the blood vessels of white fat. The second part is a piece meant to switch on a cell's built-in self-destruct program, called apoptosis, once the molecule arrives. So one part of the design is studied as a way to steer the molecule to a chosen tissue's blood supply. The other part is studied for its ability to trigger that self-destruct signal. This "address plus payload" setup, an address that finds the target and a payload that acts on it, shows up again and again in this field. Adipotide is often used as the go-to example when researchers talk about molecules aimed at blood vessels.
Because Adipotide is a research compound and not an approved product, labs that study peptides follow set procedures when they prepare and store it. In general terms, it usually arrives as a dried powder, and researchers mix it back into liquid in the lab using bacteriostatic water before any benchtop work. People who are new to working with dried peptides often read general background such as this guide to reconstituting peptides before they plan an experiment.
The Proposed Mechanism: Targeting Adipose Vasculature
The main idea behind Adipotide is that white fat, much like a tumor, leans on its own network of blood vessels to survive. The thinking is that if you could shut down just that network, the fat tissue might shrink. In published research, the CKGGRAKDC homing piece was reported to stick to a protein called prohibitin. That same work suggested prohibitin sits on the blood vessels of fat tissue and could act like a flag that marks them. By joining the homing piece to the self-destruct piece, researchers looked at whether they could set off that self-destruct signal in the cells lining fat's blood vessels only, instead of all over the body.
Later studies that map out blood vessels have kept looking at prohibitin in white fat, which is part of why the protein became such a focus for designing these targeted molecules. In this framing, prohibitin acts as the "address" that the homing piece is meant to recognize. It is worth being clear that these are descriptions of how the molecule may work, drawn from animal and lab studies. The research does not show any result in people. Scientists are still studying how precisely these molecules hit their target, whether they end up in places they should not, and how the body handles them.
Preclinical Status and Open Research Questions
Adipotide is best thought of as an early-stage research compound that has only been studied before the human-trial stage. The published work that first laid out the targeting idea was done in animals. A lot of the related research is really about the basic biology of fat's blood vessels, not about any set treatment plan. Researchers who study the compound have raised several open questions. How much does the prohibitin protein show up in one tissue versus another? How well does the homing piece actually stick to the right target and nothing else? And once the self-destruct piece is in the body, how is it processed and how long does it last? These are exactly the kinds of unknowns that careful lab studies are built to test.
For researchers comparing Adipotide to other metabolic-research molecules, organized catalogs and lookup tools can help. The research finder is one way to look up compounds by research category. Related items grouped under the metabolic and adipose research category are sorted for lab reference. As always, any experiment should be checked against the current research and your institution's own rules.
Some talk about Adipotide spreads as personal stories that have not been checked, not as results from controlled studies. BioRegen does not make or back any claims based on those stories. The right basis for understanding this research is the peer-reviewed record, not informal accounts.
Frequently Asked Research Questions
What does the abbreviation FTPP mean?
In research writing, FTPP is short for "fat-targeted proapoptotic peptide." It points to the two-part design idea: a homing piece that finds the target joined to a piece that switches on a cell's self-destruct program. That is the build researchers connect with Adipotide.
Why is prohibitin discussed alongside Adipotide?
Published research reported that the CKGGRAKDC homing piece sticks to a protein called prohibitin, and it suggested prohibitin sits on the blood vessels of white fat as a kind of marker. That link is why the protein is so central to how researchers describe the way the compound is thought to find its target.
What stage of research is Adipotide in?
Research describes it as an early-stage compound studied only in animal and lab models, before any human trials. No result in people has been shown, and it is not approved for use in humans or animals.
Selected Research References
- Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004. https://doi.org/10.1038/nm1048
- Staquicini FI, Cardo-Vila M, Kolonin MG, et al. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011. https://doi.org/10.1073/pnas.1114503108
Reference metadata sourced via PubMed.
Continue Your Research
To dig deeper into how these compounds are handled, how they compare, and how labs document them, see the BioRegen research guide, and create a free account for 10% off your first order. You can also browse the metabolic and adipose research category to see related items sorted for lab reference.
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. Statements describe published research and do not constitute any claim that any compound treats, cures, or prevents any disease.